Clovis Oncology Cost of Revenue 2011-2026 | CLVS

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Quarterly Cost of Revenue Clovis Oncology

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	8.27 M	-	-	-	9.1 M	-	-	-	-	-	4.77 M	4.49 M	4.01 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
9.1 M	4.01 M	6.13 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Exelixis EXEL	83.7 M	$ 46.2	4.01 %	$ 12.5 B	USA
Fortress Biotech FBIO	20.9 M	$ 2.49	1.22 %	$ 69.5 M	USA
Fennec Pharmaceuticals FENC	1.26 M	$ 6.85	1.93 %	$ 196 M	USA
Galapagos NV GLPG	1.63 M	$ 28.82	1.51 %	$ 2.69 B	Belgium
Grifols, S.A. GRFS	2.97 B	$ 8.4	1.51 %	$ 6.83 B	Spain
BioNTech SE BNTX	2.91 B	$ 94.21	-1.35 %	$ 27.2 B	Germany
Immuron Limited IMRN	242 K	$ 0.82	3.97 %	$ 6.82 M	Australia
Ionis Pharmaceuticals IONS	15.9 M	$ 76.34	1.45 %	$ 12.2 B	USA
Kamada Ltd. KMDA	73.3 M	$ 8.31	1.22 %	$ 260 M	Israel
Kymera Therapeutics KYMR	39.2 M	$ 85.92	3.88 %	$ 7.26 B	USA
ACADIA Pharmaceuticals ACAD	81.8 M	$ 23.02	2.98 %	$ 3.81 B	USA
Liquidia Corporation LQDA	2.86 M	$ 41.73	3.97 %	$ 3.59 B	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
MannKind Corporation MNKD	26.8 M	$ 3.88	35.49 %	$ 1.19 B	USA
AIkido Pharma AIKI	145 M	-	1.93 %	$ 17.4 M	USA
Mereo BioPharma Group plc MREO	17.9 M	$ 0.27	-3.84 %	$ 660 M	Britain
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Arcutis Biotherapeutics ARQT	36.7 M	$ 23.63	0.9 %	$ 3.01 B	USA